【摘要】 目的 评估术前卡瑞利珠单抗联合化疗治疗Ⅱ～Ⅲ期食管鳞状细胞癌的疗效及安全性。方法 回顾性分析40例可切除的食管鳞状细胞癌患者，均接受术前卡瑞利珠单抗联合化疗，化疗结束后6周进行手术。根据实体瘤疗效评价标准(RECIST)1.1和肿瘤体积指数(TVI)进行疗效评价，所有患者治疗后均接受安全性评估。结果 所有患者接受2-3个周期的术前治疗。其中10例完全缓解，21例部分缓解，8例疾病稳定，客观缓解率为77.5%,疾病控制率为97.5%。新辅助治疗后TVI明显降低(P<0.0001)。4例(10.0%)患者出现3～4级不良事件。所有患者均接受了手术治疗，且达到了R0切除。结论 术前卡瑞利珠单抗联合化疗是一种针对可切除食管鳞状细胞癌有效且耐受性较好的治疗方案。更多还原

【Abstract】 Objective To assess the therapeutic efficacy and safety of the preoperative camrelizumab combined with chemotherapy for stage Ⅱ to Ⅲ oesophageal squamous cell carcinoma(ESCC).Methods The clinical data of forty resectable ESCC patients was retrospectively analyzed.All the patients received preoperative camrelizumab with chemotherapy(PCCT).6 weeks after preoperative therapy, the patients underwent surgery.Evaluation of tumor response was performed according to Response Evaluation Criteria in Solid Tumors 1.1(RECIST 1.1)and the pathological Tumor Volume Index(TVI).The adverse response was evaluated and monitored during the treatment.Results All the patients have received 2 or 3 cycles of PCCT successfully.10 of them achieved complete response(CR),21 of them achieved partial response(PR),and 8 of them achieved stabilization of disease.The objective response rate was 77.5%,and the disease control rate(DCR)was 97.5%.The value of TVI was significantly lower after neoadjuvant therapy.4 patients(10.0%)had adverse events of grade 3 or 4.R0 resections were achieved in all patients who underwent surgery.Conclusion PCCT is an effective and tolerable treatment for resectable ESCC.更多还原